These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 11841783)

  • 1. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
    Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
    Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
    Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
    Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
    Matherly LH; Angeles SM; McGuire JJ
    Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
    Rhee MS; Galivan J; Wright JE; Rosowsky A
    Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
    Wang Y; Zhao R; Goldman ID
    Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance.
    Jansen G; Mauritz R; Drori S; Sprecher H; Kathmann I; Bunni M; Priest DG; Noordhuis P; Schornagel JH; Pinedo HM; Peters GJ; Assaraf YG
    J Biol Chem; 1998 Nov; 273(46):30189-98. PubMed ID: 9804775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway.
    Zhao R; Hanscom M; Chattopadhyay S; Goldman ID
    Cancer Res; 2004 May; 64(9):3313-9. PubMed ID: 15126375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
    Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
    Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells.
    Takemura Y; Kobayashi H; Gibson W; Kimbell R; Miyachi H; Jackman AL
    Int J Cancer; 1996 Mar; 66(1):29-36. PubMed ID: 8608962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.
    Kobayashi H; Takemura Y; Ohnuma T
    Cancer Lett; 1998 Feb; 124(2):135-42. PubMed ID: 9500202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
    Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
    Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
    Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
    Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
    Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
    Backus HH; Pinedo HM; Wouters D; Padrón JM; Molders N; van Der Wilt CL; van Groeningen CJ; Jansen G; Peters GJ
    Int J Cancer; 2000 Sep; 87(6):771-8. PubMed ID: 10956384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
    Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
    Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
    Wang Y; Zhao R; Goldman ID
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.